“Wegovy™ Demonstrated Substantial and Sustained Weight Loss in Two-Year Study in Adults With Obesity”, Novo Nordisk2021-11-05 (semaglutide; similar)⁠:

The STEP [“semaglutide Treatment Effect in People with obesity”] 5 trial demonstrated an average weight loss of 15.2% with Wegovy [weekly 2.4mg semaglutide injection] at 104 weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo

Results: from the STEP 5 phase 3b trial, presented today at the ObesityWeek2021 interactive congress, showed that adults treated with Wegovy (semaglutide) injection 2.4 mg achieved statistically-significant and sustained weight loss over the 2-year study period. [Garvey et al 2021, “Two-year Effect of Semaglutide 2.4 mg vs Placebo in Adults with Overweight or Obesity (STEP 5)”. Presented at the 39^th Annual Meeting of The Obesity Society (TOS) held at ObesityWeek, November 1–5, 2021.] The STEP 5 trial investigated Wegovy vs. placebo, both used with a reduced calorie meal plan and increased physical activity, for the treatment of obesity (BMI ≥30 kg⁄m²) or overweight (BMI ≥27 kg⁄m²) in 304 adults for 104 weeks (two years).¹

In the STEP 5 trial, results showed that Wegovy statistically-significantly reduced body weight from baseline to week 104 compared to placebo (−15.2% vs. −2.6%, estimated treatment difference: −12.6% points [95% CI: −15.3, −9.8]; p < 0.0001). The study also demonstrated that adults with overweight or obesity were more likely to lose at least 5% of their body weight with Wegovy vs. placebo (77.1% vs. 34.4%; p < 0.0001).¹

…Based on 68-week trials, the most frequently reported adverse events with Wegovy were nausea, diarrhea, vomiting, constipation, and abdominal pain.² In the STEP 5 trial, the safety profile of Wegovy was in line with previous STEP phase 3a trials; 5.9% of patients treated with Wegovy and 4.6% of patients treated with placebo permanently discontinued treatment as a result of adverse events.

Similar Links: